image
Mobile_image
eyebrow
headline

Reach your new horizon

content
Alone or in combination with chemotherapy, ADCETRIS is backed by over a decade of established clinical data and has been a trusted foundation of care that healthcare providers and patients rely on.
collection-container
card-grid-container
collection-item-type
core-card, core-text
headline

ADCETRIS is FDA approved to treat certain types of lymphoma across 8 different indications

content
To start learning about ADCETRIS, click the links below.
heading

Peripheral T-cell lymphomas

body
T-cell lymphoma is a type of blood cancer that makes up less than 15% of non-Hodgkin lymphomas. Peripheral T-cell lymphoma (PTCL) is one type of T-cell lymphoma that develops from mature forms of T cells.


Adults with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCLs), including angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphomas not otherwise specified, in combination with chemotherapy (cyclophosphamide, doxorubicin, and prednisone)

Adults with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) after systemic therapy (drugs that spread throughout the body)

Adults with systemic anaplastic large cell lymphoma (sALCL) after at least 1 combination chemotherapy treatment fails
heading

Large B-cell lymphoma including DLBCL

body

Large B‑cell lymphoma (LBCL) is a type of non‑Hodgkin lymphoma that starts in white blood cells called B cells. Diffuse Large B-cell lymphoma (DLBCL) is a type of LBCL and is the most common type of non-Hodgkin lymphoma.


Adults with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for stem cell transplant or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product

heading

Classical Hodgkin lymphoma

body
Classical Hodgkin lymphoma (cHL) is a blood cancer that starts when lymphocytes, a type of white blood cell, grow out of control.


Adults with previously untreated Stage 3 or 4 classical Hodgkin lymphoma (cHL), in combination with chemotherapy (Adriamycin (doxorubicin), vinblastine, and dacarbazine)

Adults with classical Hodgkin lymphoma (cHL) after a stem cell transplant fails or after at least 2 chemotherapy treatments fail and stem cell transplant is not an option

Adults with classical Hodgkin lymphoma (cHL) at high risk of coming back or becoming worse after a stem cell transplant (auto-HSCT)

Children 2 years of age and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with chemotherapy (doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide)
image
Mobile_image
headline

ADCETRIS is a well-established treatment backed by over a decade of clinical data

content
  • Nearly 1700 patients with certain types of lymphoma received treatment with ADCETRIS across 8 clinical trials
  • Over 67,000 patients in the US and over 183,000 patients worldwide have been treated with ADCETRIS since 2011


Healthcare providers have relied on the extensive clinical study data of ADCETRIS when treating their patients. Researchers continue to investigate ADCETRIS in clinical trials today.

collection-container
content-container
collection-container-variant
2-column
collection-item-type
core-content, core-text
headline

Talk to your doctor about ADCETRIS

content
Communicating openly with your doctor is an important part of making sure that your treatment is right for you. Your appointment is an opportunity to share symptoms, ask questions, and discuss your treatment goals. These resources are designed to help you feel confident and prepared to have those conversations with your healthcare provider.
icon
headline

ADCETRIS patient brochure

content

This brochure is intended to help build knowledge and confidence through a detailed overview of ADCETRIS and can help inform treatment discussions with your doctor.

View the brochure

icon
headline

Doctor Discussion Guide

content
It's important to ask questions and share concerns about ADCETRIS treatment with a doctor. The Doctor Discussion Guide can help you navigate the conversation, so you get the most out of your visit. Take this printable PDF with you to your next appointment.

View the guide
headline

Glossary

content

FDA: The US Food and Drug Administration.

Lymphoma: A type of blood cancer that starts in the cells of the immune system (or lymphatic system).

Mycosis fungoides (MF): Mycosis fungoides mainly affects the skin and is the most common type of cutaneous T-cell lymphoma, occurring in about 50% of cases.

Primary cutaneous anaplastic large cell lymphoma (pcALCL): A type of non-Hodgkin lymphoma that involves the skin.

Refractory: When cancer does not respond or stopped responding to treatment.

Relapse: When cancer has returned after signs and symptoms of cancer had reduced or became undetectable.

Systemic anaplastic large cell lymphoma (sALCL): A fast-growing type of T-cell lymphoma. It may appear in the skin, lymph nodes, bones, soft tissues, lungs, or liver.